These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 23256603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
    Sipe JC.
    Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
    [Abstract] [Full Text] [Related]

  • 6. Oral cladribine and fingolimod for relapsing multiple sclerosis.
    Mann H.
    N Engl J Med; 2010 May 06; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
    [No Abstract] [Full Text] [Related]

  • 7. COVID-19 in Cladribine-treated patient with multiple sclerosis.
    Haham N, Vaknin-Dembinsky A.
    J Neuroimmunol; 2021 Oct 15; 359():577690. PubMed ID: 34390951
    [Abstract] [Full Text] [Related]

  • 8. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 15; 9(3):198. PubMed ID: 19527090
    [No Abstract] [Full Text] [Related]

  • 9. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul 29; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract] [Full Text] [Related]

  • 10. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    Preziosa P, Rocca MA, Nozzolillo A, Moiola L, Filippi M.
    J Neurol; 2021 Aug 29; 268(8):2697-2699. PubMed ID: 33216223
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM.
    N Engl J Med; 2010 Feb 04; 362(5):456-8. PubMed ID: 20089958
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 04; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
    Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M.
    Expert Opin Pharmacother; 2013 Jan 04; 14(1):123-36. PubMed ID: 23256518
    [Abstract] [Full Text] [Related]

  • 17. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K.
    Mult Scler; 2018 Oct 04; 24(11):1461-1468. PubMed ID: 28817997
    [Abstract] [Full Text] [Related]

  • 18. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K, Stelmasiak Z, Grieb P.
    Mult Scler Relat Disord; 2019 Jan 04; 27():117-120. PubMed ID: 30368223
    [Abstract] [Full Text] [Related]

  • 19. Cladribine: mode of action and implications for treatment of multiple sclerosis.
    Leist TP, Weissert R.
    Clin Neuropharmacol; 2011 Jan 04; 34(1):28-35. PubMed ID: 21242742
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.